The RYR1 biobank is part of a study of the neuromuscular and multisystem features of patients with malignant hyperthermia or rhabdomyolysis related to RYR1 (ryanodine receptor type 1) variants. The main objective of the RYR1 biobank is to enable research into genetic causes and pathophysiological mechanisms, with identification of starting points for therapy. The biobank contains biomaterial (serum, heparin plasma, DNA, RNA and tissue) and clinical data from both children and adult patients.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
New Automated PBMC isolation method introduced in LMI.21 September 2021
The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.read more
Lysine Metabolism sub-biobank21 September 2021
Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.read more